A Phase 1/2, multicenter, open-label study to determine the recommended dose and regimen of durvalumab (MEDI4736) in combination with lenalidomide (LEN) with and without dexamethasone (dex) in subjects with newly diagnosed multiple myeloma (NDMM)

Trial Profile

A Phase 1/2, multicenter, open-label study to determine the recommended dose and regimen of durvalumab (MEDI4736) in combination with lenalidomide (LEN) with and without dexamethasone (dex) in subjects with newly diagnosed multiple myeloma (NDMM)

Suspended
Phase of Trial: Phase I/II

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Durvalumab (Primary) ; Lenalidomide (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 27 Sep 2017 Planned number of patients changed from 120 to 121.
    • 07 Sep 2017 According to a Celgene Corporation media release, the US FDA has placed a full clinical hold on this trial, based on risks identified in other trials for an anti-PD-1 agent, pembrolizumab, in patients with multiple myeloma in combination with immunomodulatory agents.
    • 07 Sep 2017 Status changed from recruiting to suspended, according to a Celgene Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top